Nivolumab Receives Accelerated Approval from FDA for Advanced Liver Cancer

| October 20, 2017 | 0 Comments
Nivolumab Receives Accelerated Approval from FDA for Advanced Liver Cancer

The FDA has granted accelerated approval to the immunotherapy drug nivolumab (Opdivo®) for patients with advanced liver cancer who have previously been treated with the targeted therapy sorafenib (Nexavar®).
See Original Article

Category: Recent News

About the Author ()

Leave a Reply